CASE REPORT

SPINAL MUSCULAR ATROPHY
Seema Rai¹, Santosh Bhalke², Rita Hajela³

HOW TO CITE THIS ARTICLE:

ABSTRACT: Spinal muscular atrophy is genetic disorder in which anterior horn cells in spinal cord and motor nuclei of brain stem are progressively lost. The mechanism is defect in programmed cell death, wherein the deletion of cells (A normal process during gestation) continues after birth. We are reporting a case of 25 month old male with spinal muscular atrophy type 2.

25 month old male presented with generalized hypotonic born at term gestation, product of non-consanguineous marriage, with developmental delay.

On examination muscular atrophy was present in bilateral lower limbs, generalised hypotonia present. Deep tendon reflexes absent. Power grade 3 in lower limbs and grade 4 in upper limbs. Genetic study showed deletion of exon 7 & 8 of SMN1 gene. EMG showed neurogenic pattern of fibrillation.

KEYWORDS: Atrophy, hypotonia, Apoptosis, Fasiculations.

INTRODUCTION: DISCUSSION: Spinal muscular atrophy is characterized by degeneration of motor neuron in anterior cells and motor nuclei in brainstem. SMA is of three types and associated with homozygous deletion of survival motor neuron gene in 5q 13.¹² The childhood SMA are important cause of mortality and morbidity with incidence of 1 in 6000-10000 live births.¹³

SMA is classified into three types; in type 1 severe generalized hypotonia is present. Muscle mass is thin. Deep tendon stretch muscle reflexes are absent. Patients with type 1 SMA presents in first 6 month of life. More than 65% die by 2 years.¹⁴

Type 2 characterized by progressive weakness of muscles. Patients with this type are able to suck, swallow in early infancy, confined to wheelchair by school years.¹⁴

Type 3 is mildest form of SMA shows progressive weakness proximal in distribution involving shoulder girdle. Patient are ambulatory. Longevity can extend well into middle adult life.¹⁴

DIAGNOSIS: EMG will show spontaneous discharges (fibrillation, fasciculations) at rest.⁵ The serum creatine kinase is usually normal. Deletion in survival motor neuron (SMN1) gene is identified in 92% of all classical SMA patients.⁶

TREATMENT: No medical treatment is able to delay the progression. Valproic acid can be given as it increases SMN 2 protein and sodium butyrate may slow the progression but do not alter the course of disease in all patients.⁷
CASE REPORT

BIBLIOGRAPHY:

AUTHORS:
1. Seema Rai
2. Santosh Bhalke
3. Rita Hajela

PARTICULARS OF CONTRIBUTORS:
1. Assistant Professor, Department of Pediatrics, Maharishi Markandeshwar University and Hospital, Solan.
2. Professor, Department of Pediatrics, Maharishi Markandeshwar University and Hospital, Solan.

FINANCIAL OR OTHER COMPETING INTERESTS: None

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Seema Rai,
Dev Bhoomi Green Valley D-15,
Deonghat Solan-173212, Himachal Pradesh.
E-mail: seemadoc98@yahoo.co.uk

Date of Submission: 16/08/2015.
Date of Peer Review: 17/08/2015.
Date of Acceptance: 29/08/2015.
Date of Publishing: 03/09/2015.